Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS-ACI (Cell Sheet-Autologous Chondrocyte Implantation) is an autologous cell therapy developed for the repair of articular cartilage defects, particularly in the knee. The technology involves harvesting a patient's own chondrocytes and culturing them on temperature-responsive polymer-coated surfaces to create a cohesive "cell sheet." This sheet preserves the cells' endogenous extracellular matrix (ECM) and adhesive proteins, such as fibronectin, allowing it to be transplanted directly onto the debrided cartilage defect without the need for sutures or synthetic scaffolds typically required in conventional autologous chondrocyte implantation (ACI). The therapy is designed to facilitate the regeneration of functional hyaline-like cartilage and improve structural integration with the surrounding host tissue, aiming to provide superior long-term outcomes compared to microfracture or standard ACI techniques.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cell sheet-autologous chondrocyte implantation.